Author: Zacks Small Cap Research

1676869707197690 / 966 POSTS
By John Vandermosten, CFANASDAQ:ATRSREAD THE FULL ATRS RESEARCH REPORTAntares Pharma, Inc. (NASDAQ:ATRS) reported third quarter results on November 6th posting revenue growth of 19% and achieving a quarterly sales record for the company. Earnings los ...
By John Vandermosten, CFANASDAQ:LPCNREAD THE FULL LPCN RESEARCH REPORT3Q:18 Operational and Financial ResultsLipocine (NASDAQ:LPCN) filed its 3Q:18 10-Q and posted its earnings release on November 7, 2018 reporting net loss per share of ($0.12). Thes ...
By John Vandermosten, CFANASDAQ:CORVREAD THE FULL CORV RESEARCH REPORT3Q:18 Operational and Financial ResultsCorrevio Pharma Corp. (NASDAQ:CORV) issued a press release reporting third quarter 2018 results on November 6, 2018 posting revenues of $7.0 ...
By John Vandermosten, CFATSX:RVXREAD THE FULL TSX RESEARCH REPORTCapital Raise and ConferencesFollowing its first quarter fiscal year 2019 financial filings, Resverlogix Corp. (TSX:RVX) has continued to raise capital in preparation for its expected r ...
By Brian Marckx, CFANYSE:VNRXREAD THE FULL VNRX RESEARCH REPORTQ3 Results / Operational and Business Update:VoltionRx (NYSE:VNRX) reported Q3 results and provided a business update. Relative to the financials, operating expenses of $4.5M were about 7 ...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTChicken Soup for the Soul Entertainment (NASDAQ:CSSE) reported Q3 numbers that showed remarkable progress over last year both for the quarter and the nine months. It has built a strong busi ...
By Steven Ralston, CFAOTC:MEECREAD THE FULL MEEC RESEARCH REPORTSummaryManagement has initiated a patent strategy in order to monetize aspects of SEA Technology that have been employed at over 100 EGUs. An IP (Intellectual Property) law firm has been ...
By John Vandermosten, CFANASDAQ:TTNPREAD THE FULL TTNP RESEARCH REPORTThird Quarter 2018 Financial and Operational ResultsTitan Pharmaceuticals, Inc. (NASDAQ:TTNP) reported third quarter 2018 results on November 14th in a press release and in a subse ...
By David Bautz, PhDNASDAQ:BVXVREAD THE FULL BVXV RESEARCH REPORTBusiness UpdateEnrollment of the First Influenza Season Cohort in Phase 3 Trial of M-001 CompleteBiondVax Pharmaceuticals,Ltd. (NASDAQ:BVXV) is a biopharmaceutical company developing a u ...
By Brian Marckx, CFANASDAQ:CYRXREAD THE FULL CYRX RESEARCH REPORTQ3 2018: Another Very Strong Quarter With New Records in Several Categories. Operating Leverage Continues To Solidify… Another very strong quarter for CryoPort (NASDAQ:CYRX) with Q3 set ...
1676869707197690 / 966 POSTS